KR100570959B1 - Functional Food Composition showing Anti-allergic rhinitis, Anti-atopic dermatitis and Anti-chronic asthma activity - Google Patents
Functional Food Composition showing Anti-allergic rhinitis, Anti-atopic dermatitis and Anti-chronic asthma activity Download PDFInfo
- Publication number
- KR100570959B1 KR100570959B1 KR1020040020757A KR20040020757A KR100570959B1 KR 100570959 B1 KR100570959 B1 KR 100570959B1 KR 1020040020757 A KR1020040020757 A KR 1020040020757A KR 20040020757 A KR20040020757 A KR 20040020757A KR 100570959 B1 KR100570959 B1 KR 100570959B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- weight
- food
- atopic dermatitis
- food composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 98
- 230000000694 effects Effects 0.000 title claims abstract description 22
- 235000013376 functional food Nutrition 0.000 title claims abstract description 21
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 19
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 19
- 230000003266 anti-allergic effect Effects 0.000 title claims abstract description 15
- 208000023819 chronic asthma Diseases 0.000 title claims abstract description 10
- 206010039085 Rhinitis allergic Diseases 0.000 title abstract description 17
- 201000010105 allergic rhinitis Diseases 0.000 title abstract description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 42
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 26
- 241000018646 Pinus brutia Species 0.000 claims abstract description 26
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 26
- 244000078534 Vaccinium myrtillus Species 0.000 claims abstract description 26
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 26
- 244000269722 Thea sinensis Species 0.000 claims abstract description 24
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 24
- 244000144927 Aloe barbadensis Species 0.000 claims abstract description 23
- 235000002961 Aloe barbadensis Nutrition 0.000 claims abstract description 23
- 235000009569 green tea Nutrition 0.000 claims abstract description 23
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 20
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 20
- 239000011718 vitamin C Substances 0.000 claims abstract description 20
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims abstract description 17
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims abstract description 16
- 235000013373 food additive Nutrition 0.000 claims abstract description 9
- 239000002778 food additive Substances 0.000 claims abstract description 9
- 206010039083 rhinitis Diseases 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims description 32
- 239000000284 extract Substances 0.000 claims description 31
- 235000013361 beverage Nutrition 0.000 claims description 18
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 15
- 240000006891 Artemisia vulgaris Species 0.000 claims description 15
- 230000036541 health Effects 0.000 claims description 7
- 241000196324 Embryophyta Species 0.000 claims description 5
- 235000009508 confectionery Nutrition 0.000 claims description 5
- 235000013616 tea Nutrition 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 3
- 235000021107 fermented food Nutrition 0.000 claims description 3
- 235000012149 noodles Nutrition 0.000 claims description 3
- 235000013527 bean curd Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000021109 kimchi Nutrition 0.000 claims description 2
- 235000020991 processed meat Nutrition 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 abstract description 14
- 102000003820 Lipoxygenases Human genes 0.000 abstract description 13
- 108090000128 Lipoxygenases Proteins 0.000 abstract description 13
- 230000001088 anti-asthma Effects 0.000 abstract description 9
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 8
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 abstract description 8
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 abstract description 8
- 235000008434 ginseng Nutrition 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 3
- 238000009472 formulation Methods 0.000 abstract description 3
- 239000012676 herbal extract Substances 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 43
- 230000002401 inhibitory effect Effects 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 29
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 238000002835 absorbance Methods 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 230000002292 Radical scavenging effect Effects 0.000 description 14
- 239000003963 antioxidant agent Substances 0.000 description 14
- 150000003254 radicals Chemical class 0.000 description 14
- -1 (H 2 O 2 ) Chemical class 0.000 description 13
- 229920002770 condensed tannin Polymers 0.000 description 13
- 235000018192 pine bark supplement Nutrition 0.000 description 13
- 229940106796 pycnogenol Drugs 0.000 description 13
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 12
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 12
- 229930003427 Vitamin E Natural products 0.000 description 12
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 12
- 235000013734 beta-carotene Nutrition 0.000 description 12
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 12
- 239000011648 beta-carotene Substances 0.000 description 12
- 229960002747 betacarotene Drugs 0.000 description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 12
- 235000019165 vitamin E Nutrition 0.000 description 12
- 229940046009 vitamin E Drugs 0.000 description 12
- 239000011709 vitamin E Substances 0.000 description 12
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 12
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 11
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 235000013793 astaxanthin Nutrition 0.000 description 10
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 10
- 239000001168 astaxanthin Substances 0.000 description 10
- 229940022405 astaxanthin Drugs 0.000 description 10
- 229950001002 cianidanol Drugs 0.000 description 10
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 9
- 239000000419 plant extract Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
- 230000003859 lipid peroxidation Effects 0.000 description 8
- 230000002000 scavenging effect Effects 0.000 description 8
- 241000208340 Araliaceae Species 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 7
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 6
- 235000020778 linoleic acid Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241001122767 Theaceae Species 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 244000273928 Zingiber officinale Species 0.000 description 3
- 235000006886 Zingiber officinale Nutrition 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000000924 antiasthmatic agent Substances 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 235000008397 ginger Nutrition 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 2
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- GMVPRGQOIOIIMI-DODZYUBVSA-N 7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DODZYUBVSA-N 0.000 description 2
- 244000291564 Allium cepa Species 0.000 description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 2
- 235000003097 Artemisia absinthium Nutrition 0.000 description 2
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 235000005078 Chaenomeles speciosa Nutrition 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 244000251905 Pseudocydonia sinensis Species 0.000 description 2
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 description 2
- 241000218206 Ranunculus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000001138 artemisia absinthium Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- RAZOKRUZEQERLH-UHFFFAOYSA-N capillin Chemical compound CC#CC#CC(=O)C1=CC=CC=C1 RAZOKRUZEQERLH-UHFFFAOYSA-N 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 150000001765 catechin Chemical group 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- SUBFIBLJQMMKBK-UHFFFAOYSA-K iron(3+);trithiocyanate Chemical compound [Fe+3].[S-]C#N.[S-]C#N.[S-]C#N SUBFIBLJQMMKBK-UHFFFAOYSA-K 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- GUAFOGOEJLSQBT-UHFFFAOYSA-N scoparone Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 241000092668 Artemisia capillaris Species 0.000 description 1
- 235000008658 Artemisia capillaris Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001132374 Asta Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- GSFDOOHGKOHDEL-UHFFFAOYSA-N Dalpanitin Natural products COc1cc(ccc1O)C2=COc3c(C4OC(CO)C(O)C(O)C4O)c(O)cc(O)c3C2=O GSFDOOHGKOHDEL-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 240000008670 Pinus densiflora Species 0.000 description 1
- 235000000405 Pinus densiflora Nutrition 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000014104 aloe vera supplement Nutrition 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006388 chemical passivation reaction Methods 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229940109738 hematin Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229910052640 jadeite Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- KNMNNEPMKDJBDW-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-1-(2,6-dimethylphenoxy)propan-2-amine;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CCNC(C)COC1=C(C)C=CC=C1C KNMNNEPMKDJBDW-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- SGUKUZOVHSFKPH-YNNPMVKQSA-N prostaglandin G2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](OO)CCCCC)[C@H]2C\C=C/CCCC(O)=O SGUKUZOVHSFKPH-YNNPMVKQSA-N 0.000 description 1
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- SVHDRHWULLNMQC-UHFFFAOYSA-N scoparone Natural products C1=CC(=O)OC2=C1C=C(C(=O)C)C(C(C)=O)=C2 SVHDRHWULLNMQC-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/214—Tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/708—Vitamin C
Abstract
본 발명은 우수한 항알레르기성 비염, 항아토피성 피부염 및 항만성천식 효과를 지니는 기능성 식품 조성물 및 그의 제조방법에 관한 것이다. 본 발명은 녹차, 인진쑥, 솔잎, 빌베리 및 알로에 베라로 이루어진 군으로부터 선택된 하나 이상의 복합 생약 추출물과 EGCG 및 비타민C로 구성되는 조성물을 포함하는 기능성 식품 조성물에 관한 것으로, 본 조성물은 특히 활성산소에 대하여 우수한 항산화 활성을 지닐 뿐만 아니라 리폭시게나제(Lipoxygenase)와 사이클로옥시게나제(Cyclooxygenase) 효소의 억제 및 동물 실험과 임상 실험을 통하여 본 조성물은 항알레르기성 비염, 항아토피성 피부염 및 항만성천식 효과를 나타냄을 확인하여 기능성 식품 및 식품 첨가제로서 유용한 기능성 식품 제제이다.The present invention relates to a functional food composition having an excellent antiallergic rhinitis, anti-atopic dermatitis and anti-chronic asthma effect and a method for producing the same. The present invention relates to a functional food composition comprising a composition consisting of EGCG and vitamin C and one or more complex herbal extracts selected from the group consisting of green tea, ginseng, pine needles, bilberry, bilberry and aloe vera. In addition to having excellent antioxidant activity, the composition has been shown to have anti-allergic rhinitis, anti-atopic dermatitis and anti-asthmatic effects through the inhibition of lipoxygenase and cyclooxygenase enzymes and animal and clinical trials. Functional food formulations useful as functional foods and food additives.
항알레르기성 비염, 항아토피성 피부염, 항만성천식, 리폭시게나제, 사이클로옥시게나제, 기능성 식품, 식품 첨가제.Anti-allergic rhinitis, anti-atopic dermatitis, anti-chronic asthma, lipoxygenase, cyclooxygenase, functional foods, food additives.
Description
본 발명은 항알레르기성 비염, 항아토피성 피부염 및 항만성천식 효과를 지니는 녹차, 인진쑥, 솔잎, 빌베리 및 알로에 베라의 수용성 추출물과 EGCG 및 비타민C를 포함하는 조성물에 관한 것으로, 더욱 상세하게는 상기 조성물이 여러 가지 활성산소를 소거하는 항산화 효과와 염증을 일으키는 리폭시게나제(Lipoxygenase; 이하 LO), 사이클로옥시게나제(Cyclooxygenase; 이하 COX) 억제효과 및 동물 독성실험과 임상실험을 통한 항알레르기성 비염, 항아토피성 피부염 및 항만성천식 효과를 지니는 기능성 식품 조성물에 관한 것이다.The present invention relates to a composition comprising water-soluble extracts of green tea, ginseng, pine needles, bilberry and aloe vera having anti-allergic rhinitis, anti-atopic dermatitis, and anti-asthmatic effects, EGCG and vitamin C. Antioxidative effect of the composition to eliminate various free radicals, inhibitory effect of inflammatory lipoxygenase (LO), cyclooxygenase (COX) and anti-allergic rhinitis through animal toxicity and clinical experiment The present invention relates to a functional food composition having anti-atopic dermatitis and anti-asthmatic effect.
인간을 포함한 모든 호기성 생물체는 산소를 이용한 에너지 대사 과정에서 항상 발생하는 활성산소의 상해에 대하여 근본적으로는 자기방어 기구를 구비하고 있지만, 조직의 방어능을 초월한 활성산소의 생성은 최근 성인병이라 불리는 암, 치매, 관절염, 동맥경화, 알레르기성 비염뿐만 아니라 아토피 피부염 등과 같은 염증 질환 등 여러 질환의 원인이 되고 있다(Halliwell et al., Drugs, 42, pp569-605, 1991; Fukuzawa et al., J. Act. oxyg. Free Rad., 1, pp55-70, 1990).All aerobic organisms, including humans, are equipped with self-defense mechanisms to protect against free radicals that always occur during oxygen-based energy metabolism, but the production of free radicals beyond the defenses of tissues has recently been described as a cancer called adult disease. , Dementia, arthritis, arteriosclerosis, allergic rhinitis, as well as inflammatory diseases such as atopic dermatitis (Halliwell et al., Drugs , 42 , pp569-605, 1991; Fukuzawa et al., J. Act.oxyg.Free Rad. , 1 , pp 55-70, 1990).
흔히 유해산소라 불리는 활성산소는 가장 안정한 형태의 산소인 삼중항산소(3O2)가 산화, 환원과정에서 환원되어 생성되는 일중항산소인 슈퍼옥사이드 음이온(Superoxide anion; 1O2 -)과 과산화수소(H2O 2), 하이드록시 라디칼(·OH)과 같은 짝짓지 않은 상태의 자유 라디칼로서, 이들은 단백질, DNA, 효소 및 T 세포와 같은 면역계통의 인자를 손상시켜 질환을 일으킨다(Regnstrom et al., Lancet, 16, pp1183, 1992; Gey et al., Am. Ac. J. Cin. Nutr., 53, pp326, 1991).Often free radical, called free radical is the most stable form of the oxygen in the triplet oxygen (3 O 2) oxidation, the superoxide anion singlet oxygen that is generated is reduced in the reduction process (Superoxide anion; 1 O 2 - ) and hydrogen peroxide As unpaired free radicals such as (H 2 O 2 ), hydroxy radicals (.OH), they cause diseases by damaging factors of the immune system such as proteins, DNA, enzymes and T cells (Regnstrom et al. , Lancet , 16 , pp 1 183, 1992; Gey et al., Am. Ac. J. Cin. Nutr., 53 , pp326, 1991).
이러한 이유로 항산화제의 개발 연구가 활발히 진행되어 효소 계열인 예방적 항산화제인 슈퍼옥사이드 디스무타제(Superoxide dismutase), 카탈라제(Catalase), 글루타치온퍼옥시다제(Glutathioneperoxidase) 등과 같은 항산화효소와 천연항산화제인 비타민 E, 비타민 C, 카로티노이드(Carotenoid), 글루타치온(Glutathione) 및 합성 항산화제인 부틸히드록시아니솔(t-Butyl-4-hydroxyanisole; BHA), 디부틸히드록시톨루엔(3,5-(t-Butyl)-4-hydroxytoluene; BHT) 등 많은 항산화제가 알려져 있으나, 항산화효소는 나이가 들어 노화됨에 따라 활성산소에 대한 방어능력이 감소됨에 따라 개발된 합성 항산화제의 경우는 자체의 변이원성 및 독성과 같은 문제점들이 발생되면서 보다 안전하고 효력이 강한 천연 항산화제의 개발이 절실히 요청 되고 있는 실정이다(Hatano et al., Natural Medicines, 49, pp359-363; Masaki et al., Biol. Pharm. Bull, 18, pp162-166, 1995).For this reason, researches on the development of antioxidants have been actively conducted, and antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase and other natural antioxidants such as vitamin E , Vitamin C, carotenoids, glutathione, and synthetic antioxidant butylhydroxyanisole (BHA), dibutylhydroxytoluene (3,5- (t-Butyl)- Many antioxidants such as 4-hydroxytoluene (BHT) are known, but synthetic antioxidants developed as antioxidant enzymes decrease their protection against free radicals as they age and age, causing problems such as their mutagenicity and toxicity. As a result, there is an urgent need for the development of safer and more potent antioxidants (Hatano et al., Natural Medicines , 49 , pp359-363; M asaki et al., Biol. Pharm. Bull , 18 , pp 162-166, 1995).
알레르기성 비염, 아토피성 피부염, 만성천식 및 관절염 치료에 흔히 사용되던 종래의 소염진통제는 아라키돈산을 대사하여 기관지 수축, 기관지 과민반응, 기도의 염증을 유발시키는 류코트라이인류(Leukotrienes)의 형성을 촉매 하는 LO라는 효소와 세포의 COX라는 효소를 통하여 프로스타글란딘(Prostaglandins)류 생성 대사를 억제함으로써 소염진통 효과를 나타낸다. COX는 2종류의 아이소폼(Isoform)을 가지고 있는데, COX-1은 염증 부위뿐만 아니라 정상적인 인체 여러 장기와 조직, 즉 위장관 또는 신장 등에서 프로스타글란딘류 물질을 생성하는 데에도 관여한다. 그러나 COX-2는 염증이 있는 부위에서만 작용하는 효소로 알려져 있다. 기존의 시중에서 판매되고 있는 비스테로이성 항염증제(Nonsteroidal anti-inflammatory drugs; 이하 NSAIDs)는 COX-1과 COX-2를 동시에 억제하거나 주로 COX-1을 억제하기 때문에 염증이 있는 조직뿐만 아니라, 장기간 복용 시 간, 위장관 또는 신장 등의 기능유지에 필수적인 프로스타글란딘류의 생성을 동시에 억제하여 많은 부작용을 야기하는 것으로 알려져 있다(Isselbcher et al., Harrison's Principles of Internal Medicine (13th ed) 2, pp1543-1711). 최근 개발되고 있는 선택적 COX-2 억제제(Selective COX-2 inhibitor)들은 기존의 소염진통제 효과를 그대로 유지하면서 부작용을 크게 감소시킬 수 있어 현재 그 사용이 증가되고 있는 추세이다. 따라서 LO 저해 활성과 선택적인 COX-2 저해 활성을 갖는 물질들은 부작용이 적은 알레르기성 비염, 아토피성 피부염, 만성천식 및 관절염 치료제로 사용될 수 있다Conventional anti-inflammatory drugs commonly used to treat allergic rhinitis, atopic dermatitis, chronic asthma and arthritis catalyze the formation of Leukotrienes, which metabolize arachidonic acid, causing bronchial contraction, bronchial hyperreactivity, and inflammation of the airways It has an anti-inflammatory effect by inhibiting the production of prostaglandins, through the enzyme LO and the enzyme COX. COX has two types of isoforms. COX-1 is involved in the production of prostaglandins in the organs and tissues of the human body, such as the gastrointestinal tract or kidneys, as well as inflamed areas. However, COX-2 is known to act only on the site of inflammation. Non-steroidal anti-inflammatory drugs (NSAIDs), which are commercially available on the market, inhibit both COX-1 and COX-2 at the same time, or mainly COX-1. It is known to cause many side effects by simultaneously inhibiting the production of prostaglandins, which are essential for maintaining the function of time, gastrointestinal tract or kidney (Isselbcher et al., Harrison's Principles of Internal Medicine (13th ed) 2, pp1543-1711). Selective COX-2 inhibitors, which are being developed recently, can significantly reduce side effects while maintaining the existing anti-inflammatory analgesic effect, and their use is increasing. Therefore, substances with LO inhibitory activity and selective COX-2 inhibitory activity can be used for the treatment of allergic rhinitis, atopic dermatitis, chronic asthma and arthritis with few side effects.
녹차는 차나무(Theae sinensis L., Theaceae)의 잎을 말린 것으로서 주성분은 카테친류(Catechins)이다. 이러한 카테친류에 대하여 혈압강하작용(Hara. Y et al., Nippon Nogeikagaku Kaishi, 61, pp803, 1987), 항산화작용(Matsuzaki, T et al., Nippon Nogeikagaku Kaishi, 59, pp129, 1985), 암발생 예방 작용, 충치 예방 작용 등 다양한 생리 활성이 보고되고 있으며 그 카테친류 중에서도 (-)-에피갈로카테친 갈레이트((-)-Epigallocatechingallate, 이하 EGCG)가 가장 대표적인 생리활성 물질이다.Green tea is dried leaves of Theae sinensis L. (Theaceae), and its main ingredient is catechins. Blood pressure lowering action (Hara. Y et al., Nippon Nogeikagaku Kaishi , 61 , pp803, 1987), antioxidant activity (Matsuzaki, T et al., Nippon Nogeikagaku Kaishi , 59, pp129, 1985), Various physiological activities, such as preventive action and caries prevention action, have been reported. Among the catechins, (-)-epigallocatechin gallate ((-)-Epigallocatechingallate (EGCG)) is the most representative bioactive substance.
인진쑥은 국내 각지에서 자생하는 사철쑥(Artemisia capillaris Thunb)으로 그 어린 줄기와 잎을 인진호(茵陳蒿)라 하여, 이담작용, 천식억제, 구충작용, 이뇨작용 등이 알려져 있으며, 그 성분으로는 스코파론(Scoparone), 클로로겐산(Chlorogenic acid), 카필린(Capillin) 등이 알려져 있다 (정 보섭 및 신 민교, 향약대사전, pp1016-1017, 영림사, 1998).Injin mugwort is an Artemisia capillaris Thunb that grows in various parts of Korea and its young stems and leaves are called injinho. Scoparone, chlorogenic acid, and capillin are known (Bo Bo-seop and Shin Min-kyo, Ph.D., pp1016-1017, Younglimsa, 1998).
솔잎(Pinus densiflora)은 예로부터 중풍을 예방하고 동맥경화, 고혈압, 당뇨병과 같은 노화관련 질환을 예방하는 효능이 있는 것으로 알려져 있으며 (김 완희, 최신 동의보감, pp960, 태평양출판공사), 또한 솔잎은 흰쥐에서 카드뮴 독성의 해독 (이 종섭, 박 경옥, 한국환경위생학회지, 22, pp 88-97, 1996), 체내 지방저하 효과 (이 은, 최 무영, 한국식품과학회지, 32, pp1186-1190, 2000) 항산화능 및 아질산염 소거능 (강 윤한, 박 용곤, 오 상룡, 문 광덕, 한국식품과학회지, 27, 978-984) 등의 효과가 보고되어 있다.Pine needles ( Pinus densiflora ) have long been known to be effective in preventing paralysis and preventing aging-related diseases such as arteriosclerosis, hypertension and diabetes mellitus (Kim Wan-hee, the latest Dong Bogam, pp960, Pacific Press), and pine needles in rats in the detoxification of toxic cadmium (a jongseop, foil jadeite, Korea Journal of environmental Hygiene, 22, pp 88-97, 1996) , body fat-lowering effect (this is Mooyoung Choi, Korea Food Science and Technology, 32, pp1186-1190, 2000 ) Antioxidant and nitrite scavenging activity (Kang Yoon-han, Park Yong-gon, Sang-ryong Oh, Kwang-deok Moon, Korean Society of Food Science and Technology, 27 , 978-984).
빌베리(Bilberry, Vaccinium myrtillus)는 유럽쪽에서 수천년동안 생약으로 사용되어 왔다. 빌베리 열매와 잎에는 폴리페놀이 과량 함유되어 있어 항산화제, 항염증 및 수렴제로 사용되고 있다 (Madhavi et al., Plant Science, 131, pp95, 1998: Rauha et al., Int. J. Food Microbiol, 56, pp3). Bilberry ( Vaccinium myrtillus ) has been used as a herbal medicine for thousands of years in Europe. Bilberry berries and leaves contain excessive amounts of polyphenols and are used as antioxidants, anti-inflammatory and astringents (Madhavi et al., Plant Science , 131 , pp95, 1998: Rauha et al., Int. J. Food Microbiol , 56 , pp3).
알로에 베라(Aloe vera, Aloe barbadensis Miller) 알로에 껍질을 벗겨내고 젤리질만을 사용한 것으로 이 젤리질에는 보습력이 뛰어나며 인체의 면역 증강 효과 및 상처 치유 작용이 있는 다당류(Polysaccharids)와 인체에 혈당 강하 작용을 하는 당단백(Glycoprotein) 등의 유효성분이 다량 함유되어 있다 (안 덕균, 한국 본초도감, pp280, 교학사, 2000: 김 창민, 원색 한약도감, pp306, 아카데미서적, 2001). Aloe vera (Aloe barbadensis Miller) Peeled aloe and using only jelly, this jelly has excellent moisturizing effect, polysaccharids that enhance the body's immunity and wound healing, and glycoprotein that lowers blood sugar. It contains a large amount of active ingredients such as glycoprotein (Duk-kyun Ahn, Korean Herbal Book, pp280, Kyohaksa, 2000: Changmin Kim, Primary Herbal Medicine Book, pp306, Academy Books, 2001).
본 발명자는 우수한 항산화 효과를 지니는 천연물을 문헌조사 스크리닝을 통하여 폴리페놀이 다량 함유한 녹차, 인진쑥, 솔잎, 빌베리 및 알로에 베라의 수용성 추출물과 EGCG 및 비타민 C를 배합할 경우, 우수한 항산화, 항알러지성 비염, 항아토피성 피부염, 항만성천식 및 항관절염 효과를 지니는 기능성 식품 조성물로의 적용이 가능함을 밝혀내어, 이를 토대로 본 발명을 완성하게 되었다.The inventors of the present inventors screened a natural product having excellent antioxidant effect through the screening of water-soluble extracts of green tea, phosphorus mugwort, pine needles, bilberry and aloe vera containing large amounts of polyphenols, EGCG and vitamin C. The present invention has been found to be applicable to a functional food composition having a rhinitis, anti-atopic dermatitis, anti-asthmatic and anti-arthritis effects, thereby completing the present invention.
상기의 목적을 달성하기 위하여, 본 발명은 녹차, 인진쑥, 솔잎, 빌베리 및 알로에 베라의 수용성 추출물과 EGCG 및 비타민C로 이루어진 것을 특징으로 하는 항알레르기성 비염, 항아토피성 피부염 및 항만성천식 효과를 지니는 기능성 식품 조성물을 제공한다.In order to achieve the above object, the present invention is characterized in that the anti-allergic rhinitis, anti-atopic dermatitis and anti-asthmatic effects, characterized in that the water-soluble extract of green tea, ginseng, pine needles, bilberry and aloe vera and EGCG and vitamin C Genie provides a functional food composition.
상기의 목적을 달성하기 위하여, 본 발명은 녹차, 인진쑥, 솔잎, 빌베리 및 알로에 베라로 이루어진 군으로부터 선택된 하나 이상의 복합 생약 추출물과 EGCG 및 비타민C를 필수적으로 함유하는 기능성 식품 조성물을 제공한다.In order to achieve the above object, the present invention provides a functional food composition containing essentially one or more complex herbal extracts selected from the group consisting of green tea, jinjin mugwort, pine needles, bilberry and aloe vera and EGCG and vitamin C.
구체적으로, 본 발명의 상기 조성물은 녹차 수용성 추출물 20-60 중량 %, 인진쑥 수용성 추출물 7.5-30 중량 %, 솔잎 수용성 추출물 7.5-30 중량 %, 빌베리 수용성 추출물 7.5-30 중량 % 및 알로에 베라 수용성 추출물 7.5-30 중량 %의 조성비를 갖는 식물 추출물과 EGCG 9-60 중량 % 및 비타민 C 1-30 중량 %이며, 바람직하게는 녹차 수용성 추출물 20-48 중량 %, 인진쑥 수용성 추출물 10-25 중량 %, 솔잎 수용성 추출물 10-25 중량 %, 빌베리 수용성 추출물 10-25 중량 % 및 알로에 베라 수용성 추출물 10-25 중량 %의 조성비를 갖는 식물 추출물과 EGCG 9-50 중량 % 및 비타민 C 2-10 중량 %로 구성되는 것이다.Specifically, the composition of the present invention is a water-soluble extract of green tea 20-60% by weight, 7.5-30% by weight of ginko jinja water extract, 7.5-30% by weight of pine needles water soluble extract, 7.5-30% by weight of bilberry water-soluble extract and 7.5% aloe vera water extract Plant extract having a composition ratio of -30% by weight, 9-60% by weight of EGCG and 1-30% by weight of vitamin C, preferably 20-48% by weight of green tea water-soluble extract, 10-25% by weight of water-soluble mugwort extract, pine needle water-soluble It is composed of a plant extract having a composition ratio of 10-25% by weight of the extract, 10-25% by weight of the bilberry water-soluble extract and 10-25% by weight of the aloe vera extract, and 9-50% by weight of EGCG and 2-10% by weight of vitamin C. .
본 발명의 조성물은 상기 식물 추출물 외에 추가적으로 미나리, 가시오가피, 모과, 어성초 및 생강으로 이루어진 군으로부터 선택된 1종 이상의 식물 추출물 또는 비타민류를 포함한 조성물로 제조될 수 있다.The composition of the present invention may be prepared in addition to the plant extract, in addition to the composition of at least one plant extract or vitamins selected from the group consisting of buttercup, spiny bark, Chinese quince, fish vinegar and ginger.
본 발명은 녹차, 인진쑥, 솔잎, 빌베리 및 알로에 베라를 80 내지 110 ℃에서 1 내지 5시간 열수 추출한 후, 고형분이 10 내지 40 %가 되도록 농축한 후 건조한 건조 농축물과 비타민류를 배합하여 이루어진 항알레르기성 비염, 항아토피성 피부염 및 항만성천식 효과를 지니는 기능성 식품 조성물을 제공한다.In the present invention, after extracting hot water from green tea, jinjin mugwort, pine needles, bilberry and aloe vera for 1 to 5 hours at 80 to 110 ℃, the solid content is concentrated to 10 to 40% and then dried dry concentrate and vitamins Provided is a functional food composition having allergic rhinitis, anti-atopic dermatitis and anti-chronic asthma effects.
또한, 본 발명은 녹차, 인진쑥, 솔잎, 빌베리 및 알로에 베라로 이루어진 군으로부터 선택된 하나 이상의 복합 생약 추출물과 EGCG 및 비타민C를 필수적으로 함유하는 항알레르기성 비염, 항아토피성 피부염 및 항만성천식 효과를 갖는 식품첨가제를 제공한다.In addition, the present invention provides an antiallergic rhinitis, anti-atopic dermatitis and anti-asthmatic effect, which essentially contains EGCG and vitamin C, and one or more complex herbal extracts selected from the group consisting of green tea, ginseng, pine needles, pine needles, bilberry and aloe vera. It provides a food additive having.
상기 식품첨가제는 식품 총 중량에 대하여, 0.01 중량 % 내지 10 중량 %로 포함될 수 있다.The food additive may be included in an amount of 0.01 wt% to 10 wt% based on the total weight of the food.
이하, 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 발명에 사용된 녹차, 인진쑥, 솔잎, 빌베리 및 알로에 베라 각각의 추출물을 제조하기 위해서, 구체적으로는, 녹차, 인진쑥, 솔잎, 빌베리 또는 알로에 베라를 세척 후, 그늘에서 충분히 건조시키고 세절하거나 분쇄한 다음, 무게(㎏)의 약 1배 내지 30배의 물, 에탄올과 같은 저급 알콜 또는 이들의 혼합용매, 바람직하게는 물로 20 내지 120 ℃, 바람직하게는 100 내지 110 ℃ 추출온도에서 약 1시간 내지 2일, 바람직하게는 약 2시간 내지 12시간 동안, 1회 내지 10회, 바람직하게는 2회 내지 5회 반복적으로 열수추출, 초음파 추출, 환류냉각 추출 등의 추출방법, 더욱 바람직하게는 80 내지 110 ℃에서 1 내지 5시간 열수 추출 방법에 의하여 물, 저급 알콜 또는 이들의 혼합용매에 따른 가용추출물인 조추출물을 수득하여 여과하고, 감압농축 또는 진공 농축하여 추출농축액을 수득할 수 있으며, 부가적으로 동결 건조시켜 분말형태로 수득된다.In order to prepare extracts of green tea, ginsam wormwood, pine needles, bilberry and aloe vera used in the present invention, specifically, after washing the green tea, jinjin wormwood, pine needles, bilberry or aloe vera, it is dried in a shade and then chopped or ground. Next, about 1 to 30 times the weight (kg) of water, a lower alcohol such as ethanol, or a mixed solvent thereof, preferably water, 20 to 120 ° C., preferably about 100 to 110 ° C. for about 1 hour to Extraction method such as hot water extraction, ultrasonic extraction, reflux cooling extraction, etc. repeatedly for 2 days, preferably about 2 to 12 hours, 1 to 10 times, preferably 2 to 5 times, more preferably 80 to The crude extract, which is a soluble extract according to water, lower alcohol, or a mixed solvent thereof, was obtained by filtration of hot water at 110 ° C. for 1 to 5 hours, and the filtrate was concentrated under reduced pressure or concentrated in vacuo. Condensate can be obtained and additionally lyophilized to obtain a powder.
본 발명은 상기의 제조방법으로 수득된 추출물들을 포함하는 기능성 식품 조성물을 또한 제공한다.The present invention also provides a functional food composition comprising the extracts obtained by the above production method.
본 발명 조성물의 재료로서 사용되는 생약, 식물 및 비타민류들은 직접 제조하거나 시중에서 구입하여 사용할 수도 있으며, 본 발명의 생약 또는 식물들의 추출물은 20 내지 90 % 의 고농축액의 형태 또는 분말형태로 본 식품조성물에 사용될 수 있다.The herbal medicines, plants and vitamins used as the material of the composition of the present invention may be prepared directly or purchased commercially, and the extracts of the herbal medicines or plants of the present invention may be in the form of powder or powder in the form of 20 to 90% high concentrate. It can be used in the composition.
본 발명의 기능성 식품 조성물은 건강을 위한 식품, 음료, 또는 음료첨가제로 사용할 수 있으며, 상기 기능성 조성물은 식품 총 중량에 대하여 0.01 % 내지 10 중량 %로 물에 혼합하여 항알레르기성 비염, 항아토피성 피부염 및 항만성천식을 목적으로 한 기능성 음료 또는 상기 조성 성분을 건조 분말화하여 충진한 연질 또는 경질 캡슐제, 정제, 과립, 드롭프스 및 티백 형태로 이용하는 것이 바람직하다.Functional food composition of the present invention can be used as a food, beverage, or beverage additives for health, the functional composition is mixed with water at 0.01% to 10% by weight relative to the total weight of food, anti-allergic rhinitis, anti-atopic It is preferable to use in the form of soft or hard capsules, tablets, granules, drops and tea bags filled with dry powdered functional drinks or the above-mentioned ingredients for the purpose of dermatitis and anti-asthma.
본 발명의 유효성분을 포함하는 조성물은 항알레르기성 비염, 항아토피성 피부염 및 항만성천식 효과를 위한 식품 및 음료 등에 다양하게 이용될 수 있다. 본 조성물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 캔디, 과자류, 차, 비타민 복합제, 건강기능 식품류 등이 있다.The composition containing the active ingredient of the present invention can be used in various ways such as food and beverages for antiallergic rhinitis, anti-atopic dermatitis and anti-asthmatic effect. Examples of the food to which the present composition can be added include various foods, beverages, gums, candy, confectionery, tea, vitamin complexes, and health functional foods.
본 발명의 음료 조성물은 지시된 비율로 필수 성분으로서 상기 생약을 함유 하는 것 외에는 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The beverage composition of the present invention has no particular limitation on the liquid component except for containing the herbal medicine as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates, etc. as additional ingredients, like ordinary drinks. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol. As flavoring agents other than those described above, natural flavoring agents (tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민류, 광물(전해질), 식이성분, 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 조성물들은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 본 발명은 요쿠르트 등의 유산균 제제 음료 또는 페이스트 등의 혼합제로 사용할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), dietary ingredients, flavoring agents such as synthetic and natural flavoring agents, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof. , Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and fruit juice beverages and vegetable beverages. The present invention can be used as a mixed agent such as lactic acid bacteria preparation beverages or pastes such as yogurt. These components can be used independently or in combination.
본 발명의 녹차, 인진쑥, 솔잎, 빌베리 및 알로에 베라 수용성 추출물과 EGCG 및 비타민 C는 독성 및 부작용은 거의 없으므로 예방 목적으로 장기간 복용 시에도 안심하고 사용할 수 있다. Green tea, ginseng mugwort, pine needles, bilberry and aloe vera water-soluble extracts of the present invention and EGCG and vitamin C have little toxicity and side effects, so can be used with confidence even for long-term use.
본 발명의 녹차, 인진쑥, 솔잎, 빌베리 및 알로에 베라 수용성 추출물과 EGCG 및 비타민 C를 함유하는 식품 조성물은 항알레르기성 비염, 항아토피성 피부염 및 항만성천식을 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중에 본 발명의 상기 식품 조성물의 양은 일반적으로 전체 식품 중량의 0.01 내지 30 중량 %로 가할 수 있으며, 음료 조성물에는 100 ㎖를 기준으로 0.02 내지 30 g, 바람직하게는 0.3 내지 1 g의 비율로 본 발명의 식품조성물을 가할 수 있다. Green tea, ginseng, pine needles, pine needles, bilberry and aloe vera water-soluble extracts and food compositions containing EGCG and vitamin C can be added to food or beverages for the purpose of anti-allergic rhinitis, anti-atopic dermatitis and anti-chronic asthma. . At this time, the amount of the food composition of the present invention in the food or beverage may generally be added at 0.01 to 30% by weight of the total food weight, the beverage composition is 0.02 to 30 g based on 100 ml, preferably 0.3 to 1 The food composition of the present invention can be added at a ratio of g.
또한, 본 발명은 상기 녹차, 인진쑥, 솔잎, 빌베리 및 알로에 베라 수용성 추출물과 EGCG 및 비타민 C를 필수적으로 함유하는 식품 조성물을 제과·제빵류, 면류, 두부, 육가공류, 김치를 포함한 발효식품 등의 식품가공 생산 공정 과정이나 완제품 상에 5 내지 50,000 ppm의 농도로 첨가함으로서, 제품의 보존기간을 연장하고, 부패를 방지하며 유통기한을 연장시킬 수 있는 천연보존료 기능을 갖는 식품첨가물을 또한 제공한다.In addition, the present invention is a confectionery, bakery, noodles, tofu, processed meat, kimchi fermented foods and the like, the composition containing the green tea, ginsam, pine needles, bilberry and aloe vera water-soluble extract and EGCG and vitamin C essential The addition of a concentration of 5 to 50,000 ppm on the food processing process or the finished product also provides a food additive with a natural preservative function which can extend the shelf life of the product, prevent spoilage and extend the shelf life.
또한, 본 발명은 식품첨가제를 식품에 대한 살균제, 향신료, 조미제, 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등 또는 식품소재의 필수원료로 사용하는 것을 특징으로 하는 식품첨가제의 이용방법을 제공한다. In addition, the present invention is a food additive additive, such as fungicides, spices, seasonings, various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavoring agents, colorants and neutralizing agents (cheese, chocolate, etc.) ), Pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, or the like as essential raw materials for food materials. It provides a method of using a food additive characterized in that.
이 때 식품첨가제는 식품을 침지, 분무 또는 혼합하여 상기 식품에 첨가할 수 있으며, 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0.01 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.At this time, the food additive may be added to the food by dipping, spraying or mixing the food, and the ratio of such additive is not so important, but it is generally selected in the range of 0.01 to about 20 parts by weight per 100 parts by weight of the composition of the present invention. to be.
식품은 과일, 야채, 과일이나 야채의 건조제품이나 절단제품, 과일주스, 야채주스, 이들의 혼합주스이거나 산성음료수를 포함하는 음료류, 쿠키, 사탕, 카라멜, 껌 등과 같은 제과류, 제빵류, 아이스크림 제품류, 다(茶)류, 요구르트와 같은 발효유식품, 유가공식품, 양념류, 주류, 통조림 또는 병조림류, 면류, 축산 가공식품, 수산가공식품, 미생물발효식품, 두류식품, 곡류식품, 육가공류, 감초류, 허브류 중 어느 하나 또는 하나 이상이다.Food products include fruits, vegetables, dried or cut products of fruits or vegetables, fruit juices, vegetable juices, mixed juices or beverages containing acidic beverages, cookies, candies, caramels, gums, etc. Fermented dairy foods such as tea, tea, yogurt, dairy foods, condiments, alcoholic beverages, canned or bottled foods, noodles, livestock processed foods, fish processed foods, microbial fermented foods, legumes foods, cereals, meat products, licorice , Herbs or any one or more.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예 및 실험예를 제시한다. 그러나 하기의 실시예 및 실험예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐 본 발명이 하기의 실시예 및 실험예에 한정되는 것은 아니다. Hereinafter, preferred examples and experimental examples are presented to help understand the present invention. However, the following Examples and Experimental Examples are provided only to more easily understand the present invention, and the present invention is not limited to the following Examples and Experimental Examples.
실시예 1. 필수 식물 추출물 제조예Example 1 Preparation of Essential Plant Extracts
(주)농림생약(Nong-lim herbs medicine사, Korea)에서 구입한 녹차, 솔잎, 인진쑥, 빌베리 및 알로에 베라를 각각 30 g씩을 물 600 ㎖에 넣고 110 ℃에서 3시간 열수 추출을 하여 열수 추출물을 얻었고 이를 진공농축기(Buchi R-114, Buchi사, Switzerland)로 고형분이 30 %가 될 때까지 농축하고, 그 농축물을 동결건조기(FD 5512, Ilsin사, Korea)로 동결 건조하여 완성된 녹차, 솔잎, 인진쑥, 빌베리 및 알로에 베라를 각각 2.5, 2.3, 2.8, 1.4 및 1.0g 건조 분말을 제조 하였다. 30 g of green tea, pine needles, Injin mugwort, bilberry and aloe vera purchased from Nong-lim herbs medicine Co., Ltd. in 600 ml of water and extracted with hydrothermal extract for 3 hours at 110 ℃ Green tea, which was obtained by vacuum concentration (Buchi R-114, Buchi, Switzerland) until the solid content reached 30%, and the concentrate was freeze-dried with a freeze-dryer (FD 5512, Ilsin, Korea), Pine needles, ginseng, bilberry and aloe vera prepared 2.5, 2.3, 2.8, 1.4 and 1.0 g dry powder, respectively.
실시예 2. 기타 식물 추출물 제조예Example 2. Other Plant Extract Preparation Example
각 30 g씩의 미나리, 가시오가피, 모과, 어성초, 생강 및 양파를 상기 실시예 1에 기재된 제조공정과 동일한 과정을 거쳐 그 건조분말들을 각각 2.1, 1.8, 2.5, 2.8, 3.0 및 2.5 g 건조 분말을 제조하였다. Each 30 g of buttercups, spiny ginseng, Chinese quince, fish vinegar, ginger and onion were subjected to the same process as described in Example 1, and the dried powders were respectively dried 2.1, 1.8, 2.5, 2.8, 3.0 and 2.5 g dry powder. Prepared.
실시예 3. 기능성 식품 조성물 제조예 1Example 3 Functional Food Composition Preparation Example 1
상기 실시예 1에서 제조된 녹차, 인진쑥, 솔잎, 빌베리 및 알로에 베라 수용성 추출물과 EGCG (DSM, 스위스) 및 비타민 C (DSM, 스위스)를 고형분 함량% 기준으로 각각 33 %, 8 %, 8 %, 8 %, 8 %, 25 % 및 10 %의 배합비로 배합하여 본 발명의 기능성 식품 조성물을 제조하였다.Green tea, Injin mugwort, pine needle, bilberry and aloe vera water-soluble extract prepared in Example 1, EGCG (DSM, Switzerland) and vitamin C (DSM, Switzerland) based on the solids content of 33%, 8%, 8%, respectively Functional food compositions of the present invention were prepared by blending at a blending ratio of 8%, 8%, 25% and 10%.
실험예 1. 본 발명의 각 식물 추출물 및 비타민 C의 항산화 효과 실험Experimental Example 1. Antioxidative effect experiment of each plant extract and vitamin C of the present invention
본 발명의 실시예 1 및 실시예 2에서 제조한 식물 추출물 및 비타민 C의 항산화 효능을 확인하기 위하여, 자유 라디칼인 1,1-디페닐-2-피크릴히드라질(1,1-diphenyl-2-picrylhydrazyl; 이하 DPPH)을 이용하여 문헌에 기재된 실험 과정을 응용하여 실험을 수행하였다(Yasushi, S et al., Chem. Pharm. Bull. 47, pp1369, 1999).In order to confirm the antioxidant efficacy of the plant extract and vitamin C prepared in Examples 1 and 2 of the present invention, the free radical 1,1-diphenyl-2-picrylhydrazyl (1,1-diphenyl-2 Experiments were performed using the experimental procedure described in the literature using -picrylhydrazyl (hereinafter DPPH) (Yasushi, S et al., Chem. Pharm. Bull. 47, pp1369, 1999).
2 × 10-4 M 농도가 되도록 에탄올에 용해시켜 제조한 DPPH 1.5 ㎖, 실시예 1 및 실시예 2의 추출물 시료(1000 ppm-30 ppm)와 비타민 C(1000 ppm)를 각각 0.15 ㎖, 증류수 1.35 ㎖을 첨가하여 30분간 실온에서 반응시킨 후, 520 nm에서 흡광도를 UV-VIS spectrophotometer (Spectronic genesys 5, Milton Roy사, USA)를 이용하여 측정하였다. 1.5 mL of DPPH prepared by dissolving in ethanol to a concentration of 2 x 10 -4 M, 0.15 mL of extract samples of Examples 1 and 2 (1000 ppm-30 ppm) and vitamin C (1000 ppm), respectively, and 1.35 of distilled water. After adding mL and reacting at room temperature for 30 minutes, the absorbance at 520 nm was measured using a UV-VIS spectrophotometer (Spectronic genesys 5, Milton Roy, USA).
본 발명 시료들의 DPPH 소거 효과는, 하기와 같은 수학식 1을 이용하여 계산된 DPPH 라디칼 소거활성 값이 50 % 이상인 시료에 대해서 IC50(50 % Inhibitory activity)을 비교하였다. DPPH scavenging effect of the samples of the present invention, the IC 50 (50% Inhibitory activity) was compared to the sample having a DPPH radical scavenging activity value of 50% or more calculated using Equation 1 as follows.
= ((Acontrol-Bcontrol) - (Asample-Bsample)) / (A control-Bcontrol) × 100= ((A control -B control )-(A sample -B sample )) / (A control -B control ) × 100
Acontrol : 시료를 첨가하지 않은 대조군의 흡광도A control : Absorbance of control group without sample
Asample : 시료를 첨가한 반응군의 흡광도A sample : Absorbance of reaction group to which sample is added
Bcontrol : DPPH를 첨가하지 않은 대조군의 흡광도B control : Absorbance of control group without DPPH
Bsample : DPPH를 첨가하지 않은 반응군의 흡광도B sample : Absorbance of reaction group without DPPH
그 결과, 하기 표 1에는 11가지 식물추출물과 비타민 C 각각 1000 ppm 농도 에서 DPPH를 이용한 자유라디칼의 소거 효과를 측정한 것을 나타내었고, DDPH를 이용한 자유라디칼 소거 효과가 탁월한 것으로 나타난 녹차, 인진쑥, 솔잎, 빌베리, 알로에 베라 및 비타민 C들의 항산화 효과를 IC50값으로 나타내어 하기 표 2에 나타내었다. As a result, Table 1 below shows the scavenging effect of free radicals using DPPH at 1000 ppm concentrations of 11 plant extracts and vitamin C, respectively, and green tea, jinjin mugwort and pine needles showed excellent free radical scavenging effect using DDPH. The antioxidant effects of, bilberry, aloe vera and vitamin C are shown in Table 2 below IC 50 value.
실험예 2. 본 발명의 기능성 조성물의 항산화 효과 실험Experimental Example 2 Antioxidant Effect of the Functional Composition of the Present Invention
실시예 3에서 제조된 본 발명의 기능성 조성물과, 양성 대조군으로 피크노제놀(Pycnogenol; Horphag사, USA), 비타민 E(Sigma사, USA, T-3251), (±)-카테친((±)-Catechin; Sigma사, USA, C-1788), 베타-카로틴(β-Carotene; Sigma사, USA, C-4582), 아스타산신 (Astaxanthin; Sigma사, USA, A-9335)에 대하여 위와 동일한 방법으로 DPPH를 이용한 자유라디칼 소거 효과를 IC50값으로 구하여 상호 비교하였다. Functional composition of the present invention prepared in Example 3, Pycnogenol (Horphag, USA), vitamin E (Sigma, USA, T-3251), (±) -catechin ((±) -Catechin as a positive control DPPH in the same manner as above for Sigma, USA, C-1788), beta-carotene (β-Carotene; Sigma, USA, C-4582), astaxanthin (Sigma, USA, A-9335); The free radical scavenging effect was calculated using IC 50 and compared with each other.
실험 결과, 기존에 항산화제로 잘 알려진 상용의 비타민 E, 베타-카로틴, 피크노제놀, 아스타산틴들의 개개의 효과보다 본 발명의 실시예 3에서 제조된 기능성 조성물이 탁월한 효과를 나타냄을 확인할 수 있었다 (표 3 참조).As a result, it was confirmed that the functional composition prepared in Example 3 of the present invention exhibited an excellent effect than the individual effects of conventional vitamin E, beta-carotene, pycnogenol, and astaxanthin, which are well known as antioxidants (Table 3 Reference).
실험예 3. 본 발명의 기능성 조성물의 슈퍼옥사이드 음이온(Superoxide anion) 라디칼 소거 효과Experimental Example 3. Superoxide anion radical scavenging effect of the functional composition of the present invention
슈퍼옥사이드 음이온(anion) 라디칼 소거 효과 측정은 슈퍼옥사이드 디스무타제(Superoxide dismutase; SOD) 활성 검출 키트 (435-70601, Wako사, Japan) 방법을 변형하여 사용하였다.Superoxide anion radical scavenging effect measurement was used by modifying the method of Superoxide dismutase (SOD) activity detection kit (435-70601, Wako, Japan).
실시예 3의 기능성 조성물 및 양성대조군의 시료 0.05 ㎖(500 ppm ∼ 30 ppm), 발색용액 (0.4 mM 크산틴(Xanthin) + 0.1 M 인산염완충용액(Phpsphate buffer, pH 8.0) + 0.24 mM 니트로블루테트라졸리움(Nitroblue tetrazolium; NO2-TB)) 0.5 ㎖, 효소액 (0.048 unit/㎖ 크산틴옥시데이즈(Xanthine oxidase, from Butter milk) 용액 + 0.1 M 인산염완충용액(pH 8.0) 0.5 ㎖를 첨가하고 잘 혼합하여 37 ℃에서 20 분간 반응시킨 후, 반응정지액 (69 mM 소디움도데실 설페이트(Sodium dodecyl sulfate)) 1 ㎖를 첨가하여 효소반응을 정지시키고 560 nm에서 그 흡광도를 UV-VIS spectrophotometer (Spectronic genesys 5, Milton Roy사, USA)를 이용하여 측정하였다. 본 실험에 사용된 양성 대조군으로는 피크노제놀, 비타민 E, (±)-카테친, 베타-카로틴, 아스타산틴을 사용하였고, 자세한 실험방법은 하기 표 4와 같으며, 슈퍼옥사이드 음이온 라디칼 소거 효과는 하기 수학식 2와 같이 계산하여 IC50값으로 비교하여 하기 표 5에 나타내었다.0.05 ml (500 ppm to 30 ppm) of the functional composition and positive control sample of Example 3, color developing solution (0.4 mM Xanthin + 0.1 M Phosphate buffer, pH 8.0) + 0.24 mM nitroblue tetra Add 0.5 ml of Nitroblue tetrazolium (NO 2 -TB), enzyme solution (0.048 unit / ml Xanthine oxidase, from Butter milk solution + 0.5 ml of 0.1 M phosphate buffer solution (pH 8.0) and mix well After reaction at 37 ° C. for 20 minutes, 1 ml of reaction stop solution (69 mM sodium dodecyl sulfate) was added to stop the enzymatic reaction and the absorbance at 560 nm was measured by UV-VIS spectrophotometer (Spectronic genesys 5). , Milton Roy, USA.) Pycnogenol, vitamin E, (±) -catechin, beta-carotene, astaxanthin were used as positive controls used in this experiment. Superoxide anion radical To dwell effect is to calculate compared to IC 50 values as shown in equation (2) shown in Table 5.
= ((Acontrol-Bcontrol) - (Asample-Bsample)) / (A control-Bcontrol) × 100= ((A control -B control )-(A sample -B sample )) / (A control -B control ) × 100
하기 표 5에서 볼 수 있는 것처럼, 실시예 3의 기능성 조성물이 슈퍼옥사이드 음이온 라디칼에 대하여 가장 탁월한 소거 효과를 나타내었고, 양성대조군으로 사용한 피크노제놀보다는 약 1.4배, (±)-카테친보다는 2배, 아스타산틴보다는 약 13배 높은 효과를 나타내었으며, 비타민 E와 베타-카로틴은 슈퍼옥사이드 음이온 라디칼 소거 효과를 거의 나타내지 못하였다. As can be seen in Table 5, the functional composition of Example 3 showed the most excellent scavenging effect against the superoxide anion radical, about 1.4 times than the Pycnogenol used as the positive control, 2 times than (±) -catechin, asta It was about 13 times higher than xanthine, and vitamin E and beta-carotene showed little superoxide anion radical scavenging effect.
실험예 4. 본 발명의 기능성 조성물의 지질과산화 억제 효과 측정 Experimental Example 4 Measurement of Lipid Peroxidation Inhibitory Effect of Functional Composition of the Present Invention
본 발명의 기능성 조성물의 지질과산화 억제능을 확인하기 위하여, 티오시안산염 철(Ferric-Thiocyanate; FTC) 방법을 이용한 지질과산화 억제 효과실험을 문헌(Takeshi et al, Food Chemistry, 75, pp237-40, 2001)에 기재된 실험 방법을 응용하여 사용하였다. In order to confirm the lipid peroxidation inhibitory ability of the functional composition of the present invention, a study on the effect of inhibiting lipid peroxidation using Ferric-Thiocyanate (FTC) method (Takeshi et al, Food Chemistry , 75 , pp237-40, 2001 The experimental method described in () was applied and used.
실시예 3에서 제조된 기능성 조성물 및 양성대조군의 각 시료 0.2 ㎖, 0.2 M 인산나트륨염 완충용액(Sodium phosphate buffer, pH 7.0) 0.5 ㎖, 에탄올로 용해한 2.5 % 리놀산(Linoleic acid) 0.5 ㎖, 0.1 M 2,2'-아조비스-2-아미디노프로판-디하이드로클로라이드(2,2'-Azobis-2-amidinopropane-dihydrochloride; 이하 AAPH) 50 ㎕를 혼합한 후, 37 ℃암소에서 반응시키면서 200분 후에 반응중인 시료 용액 0.1 ㎖을 75 % 에탄올 9.7 ㎖, 30 % 암모니움티오시안산염(Ammonium thiocyanate) 0.1 ㎖, 3.5 % 염산용액(HCl)으로 용해한 20 mM 염화제일철(FeCl2)을 첨가하여 3분동안 잘 혼합한 뒤 500 nm에서 흡광도를 UV-VIS spectrophotometer (Spectronic genesys 5, Milton Roy사, USA)를 이용하여 측정하였다. 양성 대조군으로는 피크노제놀, 비타민 E, (±)-카테친, 베타-카로틴, 아스타산틴을 사용하였다. 지질과산화 억제 활성 (%)은 하기 수학식 3을 이용하여 계산하였다.0.2 ml of each sample of the functional composition and positive control prepared in Example 3, 0.5 ml of 0.2 M sodium phosphate buffer (pH 7.0), 0.5 ml of 2.5% linoleic acid dissolved in ethanol, 0.1 M After mixing 50 µl of 2,2'-azobis-2-amidinopropane-dihydrochloride (AAPH), 200 minutes after reacting in a dark at 37 ° C 0.1 ml of the reaction sample solution was added to 9.7 ml of 75% ethanol, 0.1 ml of 30% Ammonium thiocyanate, and 20 mM ferric chloride (FeCl 2 ) dissolved in 3.5% hydrochloric acid solution (HCl) for 3 minutes. After mixing well, absorbance at 500 nm was measured using a UV-VIS spectrophotometer (Spectronic genesys 5, Milton Roy, USA). As a positive control, pycnogenol, vitamin E, (±) -catechin, beta-carotene and astaxanthin were used. Lipid peroxidation inhibitory activity (%) was calculated using the following equation (3).
= ((Acontrol-Bcontrol) - (Asample-Bsample)) / (Acontrol -Bcontrol) × 100= ((A control -B control )-(A sample -B sample )) / (A control -B control ) × 100
Acontrol : 시료를 첨가하지 않은 대조군의 흡광도A control : Absorbance of control group without sample
Asample : 시료를 첨가한 반응군의 흡광도A sample : Absorbance of reaction group to which sample is added
Bcontrol : 리놀산을 첨가하지 않은 대조군의 흡광도B control : Absorbance of control group without linoleic acid
Bsample : 리놀산을 첨가하지 않은 반응군의 흡광도B sample : Absorbance of reaction group without linoleic acid added
그 결과, 실시예 3의 기능성 조성물이 양성 대조군으로 사용한 피크노제놀, 비타민 E, (±)-카테친, 베타-카로틴, 아스타산틴의 억제효능에 비하여 각각 63 %, 22 %, 35 %, 62 %, 82 % 더 높은 억제 효능을 나타내었다(표 6 참조).As a result, the functional composition of Example 3 was 63%, 22%, 35%, 62%, 82 compared with the inhibitory effect of pycnogenol, vitamin E, (±) -catechin, beta-carotene and astaxanthin, respectively, used as a positive control. % Showed higher inhibitory efficacy (see Table 6).
실험예 5. 본 발명의 기능성 조성물의 하이드록시 라디칼 소거 효과 측정 Experimental Example 5. Determination of the hydroxy radical scavenging effect of the functional composition of the present invention
본 발명의 기능성 조성물의 하이드록시 라디칼 소거 효과를 확인하기 위하여 하이드록시 라디칼로 인한 2-데옥시리보즈(2-Deoxyribose)의 산화 저해율을 측정하는 실험을 문헌(Takeshi et al., Food Chemistry, 80, pp29-33, 2003)의 방법을 변형하여 사용하였다.In order to confirm the hydroxy radical scavenging effect of the functional composition of the present invention, an experiment for measuring the oxidation inhibition rate of 2-deoxyribose due to hydroxy radicals is described in Takeshi et al., Food Chemistry , 80 , pp29-33, 2003).
먼저, 10 mM 황산제일철(FeSO4)-EDTA 150 ㎕, 10 mM 2-데옥시리보즈 150 ㎕, 실시예 3의 기능성 조성물 또는 양성대조군 시료용액 300 ㎕, 0.2 M 인산나트륨염 완충용액(Sodium phosphate buffer, pH 7.0) 450 ㎕, 10 mM 과산화수소(H2O2) 150 ㎕, 증류수 300 ㎕를 첨가하였다. 이 반응은 H2O2를 첨가함으로써 반응이 시작된다. 37 ℃에서 4시간 반응시킨 후 2.8 % 트리클로로아세트산(Trichloro-acetic acid) 750 ㎕와 1.0 % 트리바비튜릭산 (Tribarbituric acid) 750 ㎕를 첨가하여 반응을 중지시키고 10분간 가열한 후, 얼음이 있는 상태에서 5분간 방치한 후 520 nm에서 흡광도를 UV-VIS spectrophotometer (spectronic genesys 5, Milton Roy사, USA)를 이용하여 측정하였다. 이 때, 양성 대조군으로 증류수에 용해되는 피크노제놀을 사용하였으며, 알코올 또는 디메틸설폭시드(Dimethyl sulfoxide, DMSO)에 용해되는 시료(비타민 E, (±)-카테친, 베타-카로틴, 아스타산틴)는 증류수로 용해한 시료 보다 하이드록시 라디칼이 적게 생성되어 양성대조군에서 제외시켰다. 하이드록시 라디칼 소거 효과는 하기 수학식 4를 이용하여 계산하였다.First, 150 μl of 10 mM ferrous sulfate (FeSO 4 ) -EDTA, 150 μl of 10 mM 2-deoxyribose, 300 μl of the functional composition or positive control sample solution of Example 3, and 0.2 M sodium phosphate buffer solution (Sodium phosphate) buffer, pH 7.0) 450 µl, 10 mM hydrogen peroxide (H 2 O 2 ) 150 µl, distilled water 300 µl was added. The reaction is started by adding H 2 O 2 . After 4 hours of reaction at 37 ° C., 750 μl of 2.8% Trichloroacetic acid and 750 μl of 1.0% Tribarbituric acid were added to stop the reaction and heated for 10 minutes. After standing for 5 minutes, the absorbance at 520 nm was measured using a UV-VIS spectrophotometer (spectronic genesys 5, Milton Roy, USA). At this time, Pycnogenol dissolved in distilled water was used as a positive control, and samples (vitamin E, (±) -catechin, beta-carotene, astaxanthin) dissolved in alcohol or dimethyl sulfoxide (DMSO) were used as distilled water. Less hydroxy radicals were produced than the dissolved samples and were excluded from the positive control. The hydroxy radical scavenging effect was calculated using the following equation (4).
= ((Acontrol-Bcontrol) - (Asample-Bsample)) / (A control-Bcontrol) × 100= ((A control -B control )-(A sample -B sample )) / (A control -B control ) × 100
Acontrol : 시료를 첨가하지 않은 대조군의 흡광도A control : Absorbance of control group without sample
Asample : 시료를 첨가한 반응군의 흡광도A sample : Absorbance of reaction group to which sample is added
Bcontrol : 과산화수소를 첨가하지 않은 대조군의 흡광도B control : Absorbance of control group without hydrogen peroxide
Bsample : 과산화수소를 첨가하지 않은 반응군의 흡광도B sample : Absorbance of reaction group without hydrogen peroxide
그 결과, 하기 표 7에서 볼 수 있는 것처럼, 실시예 3의 기능성 조성물은 2,000 ppm과 200 ppm에서 피크노제놀보다 각각 약 38 %, 70 %의 높은 억제 효과를 나타내었다. As a result, as can be seen in Table 7, the functional composition of Example 3 exhibited about 38% and 70% higher inhibitory effect than pycnogenol at 2,000 ppm and 200 ppm, respectively.
이상의 4가지 활성산소에 대한 항산력 측정 결과, 양성 대조군으로 사용된 피크노제놀은 지질과산화와 하이드로시 라디칼에 대한 억제능이 떨어지고, 비타민 E는 DPPH 라디칼과 슈퍼옥사이드 음이온 라디칼에 대한 억제능이 떨어지며, 베타-카로틴 그리고 아스타산틴은 DPPH 라디칼과 슈퍼옥사이드 음이온 라디칼, 지질과산화에 대한 억제능이 떨어지는 것으로 나타나 이러한 기존의 항산화제들은 몇 종류의 활성 산소를 선택적으로 억제할 뿐 여러 형태의 활성산소를 동시에 억제하지는 못하는 것으로 나타났다. 그러나 실시예 3의 기능성 조성물은 높은 항산화력을 보유할 뿐만 아니라 여러 형태의 활성산소를 동시에 억제하며, 특히 활성산소 대사 메카니즘에서 가장 강한 형태의 활성산소이자 노화와 암의 주범인 하이드로시 라디칼에 대하여 강한 억제능을 가지고 있어 활성산소로 야기되는 여러 질병에 대하여 인체를 보호할 수 있을 것을 사료된다.As a result of the antioxidative measurement of the above four active oxygen, Pycnogenol used as a positive control is less inhibitory to lipid peroxidation and hydrogen radicals, vitamin E is less inhibitory to DPPH radicals and superoxide anion radicals, beta-carotene Astaxanthin was found to be less effective in inhibiting DPPH radicals, superoxide anion radicals and lipid peroxidation. These conventional antioxidants selectively inhibit several types of free radicals but do not simultaneously inhibit several types of free radicals. . However, the functional composition of Example 3 not only possesses high antioxidant power but also simultaneously inhibits various forms of free radicals, and particularly with respect to the hydroxy radical, which is the strongest form of active oxygen in the free radical metabolism mechanism and the main culprit of aging and cancer. It is considered to have a strong inhibitory ability to protect the human body against various diseases caused by free radicals.
또한 DPPH 라디칼 소거 활성 결과에서 각각의 조성물 소거활성보다 실시예 3의 기능성 조성물의 소거활성 효과가 높은 것으로 보아 이들 성분들을 조합함으로서 상승효과(Synergy effect)가 나타나는 것으로 사료된다.In addition, in the DPPH radical scavenging activity, the scavenging effect of the functional composition of Example 3 was higher than that of each composition scavenging activity.
실험예 6. 본 발명의 기능성 조성물의 리폭시게나제(Lipoxygenase) 효소 저해효과 측정Experimental Example 6. Measurement of lipoxygenase enzyme inhibitory effect of the functional composition of the present invention
본 발명의 기능성 조성물의 항알레르기성 비염, 항아토피성 피부염, 항만성천식 및 항류마티스 관절염 효능을 확인하기 위하여 먼저 LO 저해효능을 문헌에 기재된 방법(Hyo-Jin Kim et al., J. Food Sci. Nutr., 3(3). pp216-220, 1998)을 변형하여 실험하였다. In order to confirm the efficacy of anti-allergic rhinitis, anti-atopic dermatitis, anti-asthmatic and anti-rheumatic arthritis of the functional composition of the present invention, the LO inhibitory effect was first described in the literature (Hyo-Jin Kim et al., J. Food Sci). Nutr., 3 (3) pp216-220, 1998).
0.1 M 트리스(Tris) 완충용액 (pH 8.5) 1 ㎖에 실시예 3의 기능성 조성물 20 ㎕, 200 단위(Units) 효소 (LO, type Ⅴ, Sigma사, USA, L-6632)10 ㎕를 혼합하고 실온에서 5분간 전반응 시킨 후 리놀산(Linoleic acid, 50 ㎍) 30 ㎕를 첨가하여 234 nm에서 초기반응속도를 측정하여 하기 수학식 5를 이용하여 IC50 값으로 나타내었다. To 1 ml of 0.1 M Tris buffer (pH 8.5), 20 µl of the functional composition of Example 3, 10 µl of 200 Units enzyme (LO, type V, Sigma, USA, L-6632) were mixed. to measure the initial reaction rate at 234 nm was around 5 min at room temperature by the addition of 30 ㎕ linoleic acid (linoleic acid, 50 ㎍) are shown as IC 50 value by using the equation (5).
= ((Acontrol-Bcontrol) - (Asample-Bsample)) / (A control-Bcontrol) × 100= ((A control -B control )-(A sample -B sample )) / (A control -B control ) × 100
Acontrol : 시료를 첨가하지 않은 대조군의 초기반응속도A control : Initial reaction rate of control group without sample
Asample : 시료를 첨가한 반응군의 초기반응속도A sample : Initial reaction rate of reaction group to which sample is added
Bcontrol : 리놀산을 첨가하지 않은 대조군의 초기반응속도B control : Initial reaction rate of control group without linoleic acid
Bsample : 리놀산을 첨가하지 않은 반응군의 초기반응속도B sample : Initial reaction rate of reaction group without linoleic acid
그 결과, LO에 대한 기능성 조성물의 저해활성 IC50 값은 27 ppm을 나타내었고, 60 ppm에서는 LO를 완전히 저해하였다(표 8 참조).As a result, the inhibitory activity IC 50 value of the functional composition for LO was 27 ppm, and at 60 ppm, LO was completely inhibited (see Table 8).
실험예 7. 본 발명의 기능성 조성물의 COX-1, COX-2 효소 저해효과 측정Experimental Example 7. Measurement of COX-1, COX-2 enzyme inhibitory effect of the functional composition of the present invention
본 발명의 기능성 조성물을 염증관여 효소인 COX-1, COX-2 효소에 대하여 저해 효능을 확인하기 위하여 문헌에 기재된 방법(Chintakunta et al., Eur. J. Med. Chem., 37. pp339-347, 2002)을 변형하여 실험하였으며, 사이클로옥시게나제 저해 효과는 프로스타글란딘 G2(PG G2)에서 프로스타글란딘 H2(PG H 2)로 환원되는 동안 N,N,N',N'-테트라메틸-p-페닐렌디아민(N,N,N',N'-tetramethyl-p-phenylene-The method described in the literature for confirming the inhibitory effect of the functional composition of the present invention against COX-1, COX-2 enzymes that are inflammation-inducing enzymes (Chintakunta et al., Eur. J. Med. Chem., 37. pp339-347 , 2002), and the cyclooxygenase inhibitory effect was reduced to N, N, N ', N'-tetramethyl- while reducing prostaglandin G 2 (PG G 2 ) to prostaglandin H 2 (PG H 2 ). p -phenylenediamine (N, N, N ', N'-tetramethyl- p -phenylene-
diamine, 이하 TMPD라 함)의 산화율을 측정하였다. diamine, hereinafter referred to as TMPD).
1 ㎖ 속에 100 mM 트리스(Tris)-HCl 완충액 (pH 8.0), 3 μM EDTA, 15 μM 헤마틴(Hematin), 150 단위(units) 효소 (COX-1 or COX-2, Sigma사, USA, 각각 C-0733,C-0858), 실시예 3의 기능성 조성물 및 기타 각 시료를 혼합하고 25 ℃에서 15분간 전반응 시킨 후, TMPD와 100 μM 아라키돈산(Aarachidonic acid)를 첨가하여 603 nm에서 25초 동안 TMPD가 산화되는 초기속도를 측정한 값을 하기 수학식 6 를 이용하여 IC50 값으로 나타내었다.100 mM Tris-HCl buffer (pH 8.0), 3 μM EDTA, 15 μM Hematin, 150 units enzyme (COX-1 or COX-2, Sigma, USA) in 1 mL C-0733, C-0858), the functional composition of Example 3 and each of the other samples were mixed and pre-reacted at 25 ° C. for 15 minutes, followed by addition of TMPD and 100 μM Aarachidonic acid for 25 seconds at 603 nm. The value of measuring the initial rate of oxidation of the TMPD during the time is represented by the IC 50 value using the following equation (6).
= ((Acontrol-Bcontrol) - (Asample-Bsample)) / (A control-Bcontrol) × 100= ((A control -B control )-(A sample -B sample )) / (A control -B control ) × 100
Acontrol : 시료를 첨가하지 않은 대조군의 초기반응속도A control : Initial reaction rate of control group without sample
Asample : 시료를 첨가한 반응군의 초기반응속도A sample : Initial reaction rate of reaction group to which sample is added
Bcontrol : 아라키돈산을 첨가하지 않은 대조군의 초기반응속도B control : Initial reaction rate of control group without arachidonic acid
Bsample : 아라키돈산을 첨가하지 않은 반응군의 초기반응속도B sample : Initial reaction rate of reaction group without arachidonic acid
그 결과, 기능성 조성물의 염증관여 효소 저해효과는 COX-2에서 NSAIDs계열인 인도메타신(Indomethacin)의 효과의 1.38배(2.79/2.02) 더 우수한 저해 효과를, COX-1에서는 인도메타신과 비교 시 약 100배 활성이 떨어지는 것으로 나타나, NSAIDs계열의 문제점인 높은 COX-1 저해로 인한 위장관 및 신장의 부작용을 최소화 할 수 있을 것으로 사료되며, 실제로 COX-2 IC50/COX-1 IC50 비가 인도메타신과 비교 시 155배 (139.5/0.9)떨어지는 것으로 나타나 실시예 3의 기능성 조성물이 인도메타신 보다 더 선택적으로 COX-2를 저해하는 것으로 나타났다 (표 9 참조).As a result, the inflammation inhibitory effect of the functional composition was 1.38 times (2.79 / 2.02) superior to the effect of the NSAIDs family Indomethacin in COX-2, and compared to indomethacin in COX-1. It appears to be about 100-fold less active, thus minimizing gastrointestinal and kidney side effects due to high COX-1 inhibition, which is a problem of NSAIDs. In fact, the ratio of COX-2 IC 50 / COX-1 IC 50 is indometha It was shown to be 155 folds (139.5 / 0.9) apart compared to Shin, indicating that the functional composition of Example 3 inhibited COX-2 more selectively than indomethacin (see Table 9).
실험예 8. 본 발명의 기능성 조성물의 동물 실험을 통한 독성 실험Experimental Example 8. Toxicity test through animal experiment of functional composition of the present invention
본 발명의 실시예 3의 기능성 조성물에 대한 독성 여부를 알아보기 위하여 8 주령 SD 랫트 (♂(250 g, 5마리), ♀(210 g, 5마리), 샘타코,(Samtako사, Korea) 10마리(대조군 2마리, 실험군 8마리)에 대하여 5 g/kg 농도로 1회 경구투여 하고 2주간 생존여부, 몸무게, 털의 윤기, 곤두선 상태, 배변상태, 전체적인 움직임 등 종합적인 건강상태를 확인하였다.In order to determine the toxicity of the functional composition of Example 3 of the present invention 8-week-old SD rats (♂ (250 g, 5), ♀ (210 g, 5), Samtako, (Samtako, Korea) 10 Once orally, 5 g / kg concentrations were administered to two rats (two control and eight experimental groups) and checked for overall health, including survival, weight, hairiness, bristle, bowel movement, and overall movement for two weeks. It was.
그 결과, 실시예 3의 기능성 조성물을 경구투여한 실험군 8마리 모두 생존하였고 건강상태가 양호하였으며 특이사항은 발견되지 않았다 (표 10 참조).As a result, all eight experimental groups orally administered the functional composition of Example 3 survived and were in good health and no specificity was found (see Table 10).
실험예 9. 본 발명의 기능성 조성물에 대한 임상 실험Experimental Example 9 Clinical Trials on Functional Compositions of the Invention
본 발명의 실시예 3의 기능성 조성물에 대한 인체의 알러지성 비염 효과를 알아보기 위해, 4곳의 병원에서 알러지성 비염 증상 환자 14명을 대상으로 하루 약 400 mg (1회 2정, 1일 2회)씩 복용하게 하여 간이 임상 실험을 실시하였다 (표 11 참조).In order to examine the allergic rhinitis effect of the human body on the functional composition of Example 3 of the present invention, about 400 mg per day (two tablets per day, 2 tablets per day) for 14 patients with allergic rhinitis symptoms in four hospitals Liver clinical trials were conducted (see Table 11).
그 결과, 14명의 환자들 중에서 9명이 부작용 없이 개선효과를 보였고, 증상이 매우 심한 3명의 환자를 포함하여 5명에게는 개선 효과가 보이지 않았다. As a result, 9 out of 14 patients showed improvement without side effects, and 5 did not show improvement, including 3 patients with severe symptoms.
* : 증상이 매우 심한 환자 * : Patients with very severe symptoms
제제예 1. 캡슐제의 제조Formulation Example 1 Preparation of Capsule
실시예 3의 기능성 조성물 100 ㎎100 mg of the functional composition of Example 3
유당 50 ㎎Lactose 50 mg
전분 50 ㎎Starch 50 mg
탈크 2 ㎎Talc 2 mg
스테아린산마그네슘 적량Magnesium stearate appropriate amount
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
제제예 2. 건강음료의 제조Formulation Example 2 Preparation of Health Beverage
실시예 3의 기능성 조성물 1000 ㎎1000 mg of functional composition of Example 3
구연산 100 ㎎Citric acid 100 mg
올리고당 100 g100 g oligosaccharides
정제수를 가하여 전체 900㎖Add 900 ml of purified water
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.After mixing the above components in accordance with a conventional healthy beverage manufacturing method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilized and refrigerated and then Used to prepare the healthy beverage composition of the invention.
이상 상기 실시예 및 실험예들을 통하여 설명된 바와 같이, 본 발명의 기능성 식품 조성물은 뛰어난 항알레르기성 비염, 항아토피성 피부염 및 항만성천식 효과를 가지므로, 기능성 음료, 건강 기능식품 등의 기능성 식품 분야에 유용하게 적용될 수 있다.As described above through the above Examples and Experimental Examples, the functional food composition of the present invention has excellent anti-allergic rhinitis, anti-atopic dermatitis and anti-chronic asthma effect, functional food, such as functional food, health functional food It can be usefully applied to the field.
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040020757A KR100570959B1 (en) | 2004-03-26 | 2004-03-26 | Functional Food Composition showing Anti-allergic rhinitis, Anti-atopic dermatitis and Anti-chronic asthma activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040020757A KR100570959B1 (en) | 2004-03-26 | 2004-03-26 | Functional Food Composition showing Anti-allergic rhinitis, Anti-atopic dermatitis and Anti-chronic asthma activity |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050095380A KR20050095380A (en) | 2005-09-29 |
KR100570959B1 true KR100570959B1 (en) | 2006-04-13 |
Family
ID=37275910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040020757A KR100570959B1 (en) | 2004-03-26 | 2004-03-26 | Functional Food Composition showing Anti-allergic rhinitis, Anti-atopic dermatitis and Anti-chronic asthma activity |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100570959B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101006353B1 (en) * | 2010-03-24 | 2011-01-10 | 조영관 | Stabilized ascorbic acid containing novel pharmaceutical compositions for the treatment of dermatitis |
KR101127268B1 (en) | 2009-12-16 | 2012-03-29 | 박치호 | Health foods composition for improving of allergic rhinitis |
KR20190045887A (en) | 2018-12-31 | 2019-05-03 | 류형준 | Food composition for treating chronic rhinitis |
KR20200139422A (en) | 2019-06-04 | 2020-12-14 | 원광대학교산학협력단 | Composition for anti-rhinitis comprising sword bean extract as active component |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101310981B1 (en) * | 2006-06-05 | 2013-09-25 | 충북대학교 산학협력단 | Composition For Preventing And Improving Allergic Disease Comprising Extract Of Sophorae Fructus |
CN104306950B (en) * | 2014-11-14 | 2017-08-25 | 原福利 | It is a kind of to treat External-applicationtraditional traditional Chinese medicinal of rhinitis and its production and use |
KR20210068284A (en) | 2019-12-01 | 2021-06-09 | 좋은영농조합법인 | A food composition for the improvement or prevention of asthma comprising extract of water dropwort |
-
2004
- 2004-03-26 KR KR1020040020757A patent/KR100570959B1/en active IP Right Grant
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101127268B1 (en) | 2009-12-16 | 2012-03-29 | 박치호 | Health foods composition for improving of allergic rhinitis |
KR101006353B1 (en) * | 2010-03-24 | 2011-01-10 | 조영관 | Stabilized ascorbic acid containing novel pharmaceutical compositions for the treatment of dermatitis |
KR20190045887A (en) | 2018-12-31 | 2019-05-03 | 류형준 | Food composition for treating chronic rhinitis |
KR20200139422A (en) | 2019-06-04 | 2020-12-14 | 원광대학교산학협력단 | Composition for anti-rhinitis comprising sword bean extract as active component |
Also Published As
Publication number | Publication date |
---|---|
KR20050095380A (en) | 2005-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101046621B1 (en) | Antimicrobial composition comprising sun-dried salt and koji mulberry extract | |
KR102306737B1 (en) | Antioxidant food comprising extracts of fresh sprouts of Xanthium canadense Mill. | |
AU2008307137A1 (en) | Natural preservatives and antimicrobial agents | |
KR101093998B1 (en) | Functional composition for the prevention of hangover and improving liver function | |
KR100570959B1 (en) | Functional Food Composition showing Anti-allergic rhinitis, Anti-atopic dermatitis and Anti-chronic asthma activity | |
JP2006014730A (en) | Food product | |
KR20130097537A (en) | Composition comprising mixture of hot water extract of curcuma longa radix, acorus gramineus soland and polygala tenuifolia to enhance cognition and memory | |
KR20100128941A (en) | Functional composition for the prevention and improvement of hangover, and food and food additive having the same | |
KR100510253B1 (en) | Functional Food Composition having Anti-oxidative, Anti-arthritic and Anti-dementia Activity | |
KR100768830B1 (en) | Extract of echinosophora koreensis removing hangover and having anti-oxidant activity | |
Shah et al. | Fruit and fruit products as functional foods | |
KR100758266B1 (en) | Extract of chrysanthemum zawadskii removing hangover and having anti-oxidant activity | |
KR101636608B1 (en) | Composition for antioxidation comprising the seed extract of cornus officinalis | |
KR20170077980A (en) | Antioxidant or anti-aging composition comprising extracts of fresh sprouts of Xanthium canadense Mill. | |
KR100690071B1 (en) | Functional composition for the prevention and improvement of hangover | |
Marnewick | Antioxidant properties of Rooibos (Aspalathus linearis)–in vitro and in vivo evidence | |
KR20170059221A (en) | Antioxidant or anti-aging composition comprising the extract of stem and leaf of Rubus coreanus Miquel | |
KR100872310B1 (en) | Functional composition for the cotinene metabolism improvement which is caused by with smoking and hangover removal, foods and food additive containing the same | |
JP2010043036A (en) | Saccharometabolism promoter | |
KR102184823B1 (en) | Antioxidant composition containing blackcurrant, lingonberry and sea buckthorn extract | |
Shi et al. | Functional foods from fruit and fruit products | |
KR102483814B1 (en) | Compositions for Anti-Bacterial and Anti-Inflammatory Effect Comprising Oil of Ulvoid green algae | |
KR20120017502A (en) | Composition comprising extracts of cedrela sinensis for anti-cancer activity | |
KR102295725B1 (en) | Meal substitute for liver protection based on sweet potato and a method for manufacturing the same | |
KR100758267B1 (en) | Compositions effective for removing hangover, which contain natural plant extracts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130405 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140417 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160405 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190401 Year of fee payment: 14 |